Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Joseph I. Clark, Michael K.K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, Lionel D. Lewis, John H. Stewart, Ulka Vaishampayan, Brendan Curti, René Gonzalez, Jose Lutzky, Venkatesh Rudraptna, Lee D. Cranmer, Joanne M. Jeter, Ralph J. Hauke, Gerald Miletello, Mohammed M. Milhem, Asim AminJohn M. Richart, Mayer Fishman, Sigrun Hallmeyer, Sapna P. Patel, Peter Van Veldhuizen, Neeraj Agarwal, Bret Taback, Jonathan S. Treisman, Marc S. Ernstoff, Jessica C. Perritt, Hong Hua, Tharak B. Rao, Janice P. Dutcher, Sandra Aung

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint Dive into the research topics of 'Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>'. Together they form a unique fingerprint.

Medicine & Life Sciences